Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nektar Therapeutics (NKTR) PT Raised to $35 at Jefferies; Plans '181 NDA 2 Years Early
November 8, 2017 8:28 AM ESTJefferies raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $35.00 (from $23.00) while maintaining a Buy rating following Q3 results.
Analyst David Steinberg said the big news was NKTR disclosed that they are now planning to file an NDA for 181 in Apr... More
